MedTrace Logo

A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient

NCT05493631 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-11-24

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability, pharmacokinetics and pharmacodynamics of subcutaneous MG1113 in the multiple ascending dose study in patients with severe hemophilia.

Conditions

Interventions

BIOLOGICAL

MG1113

MG1113 subcutaneous (SC) injection

Sponsors & Collaborators

  • GC Biopharma Corp

    lead INDUSTRY

Principal Investigators

  • Eun-Jin Choi · Daegu Catholic University Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-24
Primary Completion
2024-12-11
Completion
2024-12-11

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05493631 on ClinicalTrials.gov